This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

VCH-916

Vertex Pharmaceuticals Incorporated

Drug Names(s): Polymerase NNI

Description: VCH-916, a small molecule inhibitor of HCV NS5B RNA-dependent polymerase, is a novel drug for the treatment of Hepatitis C infection.

Deal Structure: VCH-916 was originally developed by ViroChem Pharma.

In March 2009, Vertex Pharmaceuticals agreed to acquire ViroChem Pharma in a stock and cash transaction. Following completion of the transaction, Vertex will own worldwide rights to ViroChem's HCV drug development portfolio. Under the terms of the agreement, which have been approved by the Boards of Directors of both companies, ViroChem shareholders will receive $100 million in cash and 9.9 million shares of Vertex common stock. The stock portion of the consideration is subject to a collar, and the actual number of shares of Vertex stock to be issued will be based on an average Vertex share price prior to the acquisition closing, but per the agreement will not exceed 11.0 million shares. Vertex expects the shares issued in this transaction will be immediately tradeable under a resale registration statement which Vertex plans to file at the time of closing. Vertex has completed its acquisition of ViroChem.


VCH-916 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug